Alul Quoted in BNA Life Sciences Law Report
Taft Pharmaceutical Litigation attorney Andrew M. Alul is quoted in the Oct. 3 article “Supreme Court Denies Review in Hatch-Waxman Case,” published in BNA’s Life Sciences Law Report. Alul commented on safe harbor protection and post-marketing activity. Read the article here.
Alul focuses his practice on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA). He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.
In This Article
You May Also Like
Taft IP Attorneys Recognized in WTR 1000 2025 Shrestha Quoted in Law360 on Skinny Label Suits